Table 1.
Self-reported characteristics of study participants
| Characteristic | Number (%) |
|---|---|
| Age | |
| 30–39 | 3 (23.1%) |
| 40–49 | 3 (23.1%) |
| 50–59 | 4 (30.8%) |
| 60–69 | 3 (23.1%) |
| Sex and Gender | |
| Male | 9 (69.2%) |
| Female | 4 (30.8%) |
| Province of residence | |
| British Columbia | 3 (23.1%) |
| Alberta | 1 (7.7%) |
| Saskatchewan | 1 (7.7%) |
| Manitoba | 1 (7.7%) |
| Ontario | 5 (38.5%) |
| New Brunswick | 1 (7.7%) |
| Nova Scotia | 1 (7.7%) |
| Specialty | |
| Paediatric neurologist | 3 (23.1%) |
| General practitioner/ family physician | 5 (38.5%) |
| Internist | 1 (7.7%) |
| Paediatrician | 2 (15.4%) |
| Paediatric psychiatrist | 2 (15.4%) |
| Race | |
| Caucasian | 9 (69.2%) |
| Caucasian (Central Eastern) | 1 (7.7%) |
| Latin American | 1 (7.7%) |
| Jewish | 1 (7.7%) |
| Metis | 1 (7.7%) |
| Estimated number of children receiving authorization for medical cannabis | |
| 5–15 | 3 (23.1%) |
| 20–45 | 4 (30.7%) |
| 100 + | 6 (46.2%) |
| Indications* | |
| Treatment resistant seizure disorders | 10 (76.9%) |
| Autism | 10 (76.9%) |
| Other treatment resistant behavioural or mental health disorders | 10 (76.9%) |
| Chronic pain, palliative care, cancer | 3 (23.1%) |
| Other | 2 (15.4%) |
| Experience dealing with schools | |
| None (doses exclusively around school hours) | 3 (23.1%) |
| Limited (between one and a few encounters) | 5 (38.5%) |
| Several (many encounters) | 5 (38.5%) |
*Percentage will not add up to 100 since some participants stated more than one answer.